Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11224155 | 0.89 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL21096753 | 0.89 | — | — | |
| SCHEMBL23888763 | 0.86 | MC4R (0.31) | MC4R | |
| SCHEMBL15191317 | 0.81 | MC4R (0.35) | MC4RNCF1CHRM2CHRM4CHRM5 | |
| SCHEMBL1613074 | 0.79 | — | — | |
| SCHEMBL12714695 | 0.79 | — | — | |
| SCHEMBL1613076 | 0.79 | — | — | |
| SCHEMBL15955649 | 0.77 | CYP3A4 (0.36) | CYP2D6ALDH1A1 | |
| SCHEMBL23134687 | 0.77 | MC4R (0.39) | MC4RCHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL2171359 | 0.77 | CYP3A4 (0.36) | CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127025-B1 | COMPOSITION FOR COPPER BUMP ELECTRODEPOSITION COMPRISING A POLYAMINOAMIDE TYPE LEVELING AGENT | BASF SE (DE) | 2025-10-01 | — | — | EP | disclosed |
| US-12134834-B2 | Composition for copper bump electrodeposition comprising a polyaminoamide type leveling agent | BASF SE (DE) | 2024-11-05 | — | — | US | disclosed |
| US-20230142238-A1 | COMPOSITION FOR COPPER BUMP ELECTRODEPOSITION COMPRISING A POLYAMINOAMIDE TYPE LEVELING AGENT | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4127025-A1 | COMPOSITION FOR COPPER BUMP ELECTRODEPOSITION COMPRISING A POLYAMINOAMIDE TYPE LEVELING AGENT | BASF SE (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335434-A | Composition for copper bump electrodeposition comprising polyaminoamide type leveling agent | 巴斯夫欧洲公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021197950-A1 | COMPOSITION FOR COPPER BUMP ELECTRODEPOSITION COMPRISING A POLYAMINOAMIDE TYPE LEVELING AGENT | BASF SE (DE) | 2021-10-07 | — | — | WO | disclosed |
| WO-2019060860-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-03-28 | — | — | WO | disclosed |
| EP-2361242-B1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS SA (ES) | 2018-08-01 | — | — | EP | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| EP-3126337-A2 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100282081-A1 | ABSORBENT LIQUID, AND APPARATUS AND METHOD FOR REMOVING C02 OR H2S FROM GAS WITH USE OF ABSORBENT LIQUID | YOSHIYAMA RYUJI | 2010-11-11 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090277330-A1 | Absorbent Liquid, and Apparatus and Method for Removing CO2 or H2S from Gas with Use of Absorbent Liquid | MITSUBISHI HEAVY INDUSTRIES, LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-4145347-A | TREATMENT OF SENILITY, AMNESIA AND LEARNING DISORDERS | PARKE, DAVIS & COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | MC4R 3574/4885NCF1 1233/4885CHRM2 3439/4885 |
| US-20100282081-A1 | ABSORBENT LIQUID, AND APPARATUS AND METHOD FOR REMOVING C02 OR H2S FROM GAS WITH USE OF ABSORBENT LIQUID | ALKBH2, ALKBH1, CNR2 | MC4R 4421/4885NCF1 1774/4885CHRM2 11/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MC4R 2152/4885NCF1 3318/4885CHRM2 3305/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | MC4R 4509/4885NCF1 584/4885CHRM2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.